In 2026, India’s pharmaceutical stocks are making headlines with impressive year-to-date gains. This surge is driven by strong domestic demand alongside enhanced profitability from new product launches. Notable players like Laurus Labs and Gland Pharma have recorded remarkable returns, topping 100%. Amid challenges faced by other sectors, the pharmaceutical field demonstrates resilience. Analysts are optimistic but advise exercising caution regarding potential market volatility and the durability of this sector’s performance.
Rs 40,000 crore in 13 days! Is the great FII reversal finally here to save Nifty bulls?
Foreign institutional investors have pumped nearly Rs 40,000 crore into Indian equities in 13 trading sessions, raising hopes of a sustained reversal after months of
November 5, 2026